N4P has announced the raising of additional development capital amounting to c.£2.03m (gross) from a placing of c.50.7m new ordinary shares at a price of 4.0p each.
Significantly, the Group’s unique silica nanoparticle delivery system, Nuvec®, has already demonstrated that is capable of loading and transfecting both DNA and mRNA and producing an immune response. Focus now is on a phased work program designed to make Nuvec® more consistent, easier to handle and therefore more efficacious.
While N4P’s virtual model and contracted laboratories have ensured its testing schedules have not been significantly hindered by the lockdown, the COVID-19 Pandemic has nevertheless provided it with an ideal opportunity to demonstrate how Nuvec® could substantially enhance delivery of a potential Coronavirus vaccine, as well as developments of other viruses that may well surface in the future.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to N4 Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
